Teva Pharmaceutical Industries Limited Stock Other OTC
Stocks
TEVJF
IL0006290147
Pharmaceuticals
OTC Markets Traded| Market Cap | 42.85B 37.01B 34.78B 31.63B 59.46B 4,097B 60.44B 407B 159B 2,052B 161B 157B 6,818B | P/E 2026 * |
49.3x | P/E 2027 * | 20.2x |
|---|---|---|---|---|---|
| Enterprise Value | 54.73B 47.27B 44.42B 40.39B 75.94B 5,233B 77.2B 520B 203B 2,621B 205B 201B 8,708B | EV / Sales 2026 * |
3.3x | EV / Sales 2027 * | 2.97x |
| Free-Float |
88.59% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 01/01/2023 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 22/12/2019 |
Matthew Shields
COO | Chief Operating Officer | 52 | 03/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 01/01/2009 |
Sol Barer
CHM | Chairman | 78 | 06/02/2017 |
Rosemary Crane
BRD | Director/Board Member | 65 | 01/09/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 42.85B | |
| -2.25% | -0.47% | +68.30% | +115.90% | 1,052B | |
| -0.66% | +0.43% | +47.39% | +50.54% | 627B | |
| -0.54% | +1.39% | +20.69% | +63.99% | 441B | |
| -1.99% | -3.32% | +38.71% | +35.41% | 349B | |
| -1.05% | -2.81% | +23.07% | +35.70% | 287B | |
| -2.12% | -3.67% | -1.14% | +5.37% | 241B | |
| -0.63% | +1.04% | +40.05% | +56.09% | 224B | |
| -1.19% | -3.41% | -9.57% | -52.71% | 202B | |
| +0.16% | +3.87% | +16.89% | +73.73% | 172B | |
| Average | -1.03% | +0.43% | +27.15% | +42.67% | 399.46B | |
| Weighted average by Cap. | -1.34% | +0.32% | +39.09% | +61.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.58B 14.32B 13.46B 12.24B 23.01B 1,586B 23.39B 158B 61.66B 794B 62.26B 60.91B 2,639B | 17.3B 14.95B 14.04B 12.77B 24.01B 1,655B 24.41B 165B 64.34B 829B 64.97B 63.56B 2,754B |
| Net income | 1.14B 985M 926M 842M 1.58B 109B 1.61B 10.85B 4.24B 54.61B 4.28B 4.19B 181B | 2.34B 2.02B 1.9B 1.72B 3.24B 223B 3.3B 22.22B 8.69B 112B 8.77B 8.58B 372B |
| Net Debt | 11.88B 10.26B 9.64B 8.77B 16.48B 1,136B 16.75B 113B 44.16B 569B 44.59B 43.63B 1,890B | 8.61B 7.44B 6.99B 6.36B 11.95B 823B 12.15B 81.89B 32.02B 412B 32.33B 31.63B 1,370B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
